Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Kestra Advisory Services LLC

Kestra Advisory Services LLC raised its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 25.4% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,628 shares of the biopharmaceutical company’s stock after acquiring an additional 735 shares during the quarter. Kestra Advisory Services LLC’s holdings in Regeneron Pharmaceuticals were worth $2,751,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. BlackRock Inc. acquired a new position in Regeneron Pharmaceuticals in the second quarter valued at approximately $5,682,636,000. State Street Corp increased its stake in Regeneron Pharmaceuticals by 3.6% in the second quarter. State Street Corp now owns 4,834,688 shares of the biopharmaceutical company’s stock valued at $3,014,621,000 after purchasing an additional 170,210 shares during the last quarter. Bank of America Corp DE raised its holdings in Regeneron Pharmaceuticals by 2.8% during the first quarter. Bank of America Corp DE now owns 1,189,584 shares of the biopharmaceutical company’s stock worth $919,120,000 after purchasing an additional 32,158 shares in the last quarter. Amundi raised its holdings in Regeneron Pharmaceuticals by 27.5% during the first quarter. Amundi now owns 1,009,798 shares of the biopharmaceutical company’s stock worth $780,210,000 after purchasing an additional 217,892 shares in the last quarter. Finally, Legal & General Group Plc acquired a new stake in Regeneron Pharmaceuticals during the second quarter worth approximately $473,872,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, insider Andrew J. Murphy sold 4,147 shares of the stock in a transaction on Wednesday, October 14th. The stock was sold at an average price of $772.70, for a total transaction of $3,204,386.90. Following the transaction, the insider owned 47,833 shares of the company’s stock, valued at $36,960,559.10. This represents a 7.98% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the stock in a transaction on Friday, October 30th. The stock was sold at an average price of $900.00, for a total value of $360,000.00. Following the transaction, the director directly owned 603 shares in the company, valued at approximately $542,700. This represents a 39.88% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 27,028 shares of company stock worth $25,025,950 in the last three months. 6.97% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $955.47 on Monday. The company has a current ratio of 3.35, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The company’s 50-day moving average price is $816.17 and its 200 day moving average price is $747.36. Regeneron Pharmaceuticals, Inc. has a 52 week low of $591.52 and a 52 week high of $991.73. The stock has a market cap of $98.84 billion, a price-to-earnings ratio of 21.10, a PEG ratio of 1.26 and a beta of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last released its quarterly earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share for the quarter, topping the consensus estimate of $16.51 by $3.56. The company had revenue of $5.12 billion during the quarter, compared to the consensus estimate of $4.58 billion. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. Regeneron Pharmaceuticals’s revenue was up 36.3% compared to the same quarter last year. During the same quarter last year, the business posted $11.83 earnings per share. As a group, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 58.26 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 3rd. Investors of record on Friday, November 20th will be given a dividend of $0.94 per share. The ex-dividend date is Friday, November 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.4%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.30%.

Analysts Set New Price Targets

REGN has been the topic of several research analyst reports. Argus upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $850.00 price target on the stock in a research note on Thursday, October 1st. Zacks Research upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 28th. Truist Financial upped their price objective on shares of Regeneron Pharmaceuticals from $780.00 to $982.00 and gave the company a “buy” rating in a research note on Monday, November 2nd. Wall Street Zen raised Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Sunday, September 20th. Finally, Weiss Ratings upgraded Regeneron Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a research report on Monday, November 2nd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $898.97.

View Our Latest Analysis on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Company Profile

(Free Report)

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions. The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.

See Also

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.